TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07490262: A Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy as First-line Treatment in Previously Untreated Patients With Unresectable or Metastatic Hepato

Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 680 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT07490262 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07490262 Rescue Dossier →